ArcelorMittal has been active in reshaping its asset portfolio, including strategic acquisitions and expansion in the North American market to reduce exposure to potential tariffs. The company has ...

Universal Entertainment’s consolidated EBITDA is expected to recover from ¥21.2 billion in fiscal 2024 to about ¥29 billion this fiscal year, which is about 70% of the EBITDA recorded in a relatively ...

Ratings has upgraded its long-term issuer credit rating for online travel agency eDreams ODIGEO S.A. to ’B+’ from ’B’. This upgrade follows eDreams’ strong operating performance for fiscal 2025, which ...

The short seller’s analysis also calls into question GRAIL’s claims of the Galleri test’s positive predictive value (PPV), suggesting that the company’s comparisons to standard screening tools are ...

Joe Ovsenek, President and CEO of Tudor Gold, stated, "Our acquisition of American Creek cements our interest in the Treaty Creek Project, which hosts one of the largest gold discoveries in Canada ...

Corp to Equal-weight from Overweight, saying the fast-food giant’s stock already reflects much of its near-term improvement, ...

Shares of Plug Power Inc (NASDAQ:PLUG) surged 8.3% following the announcement of a significant expansion of its partnership ...

Shares of Ondas Holdings Inc. (NASDAQ:ONDS) surged 11.2% following the announcement of a substantial $14.3 million purchase order from a key defense customer for multiple units of its Optimus System, ...

Shares of PolyPid Ltd. (NASDAQ: PYPD) soared 10.1% following the announcement of positive Phase 3 trial results for its D-PLEX100 product, aimed at preventing sur ...

The clinical hold’s removal has been positively received by the market as it signals a step forward for TuHURA’s IFx-2.0, which is being developed as an adjunctive therapy in combination with ...

Investing.com -- Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) fell 1.2% following the U.S. Food and Drug Administration’s (FDA) Refusal to File (RTF) letter regarding the company’s New Drug ...

Approximately 5.1% of Elevation Oncology’s common stock is held by officers, directors, and affiliates who have agreed to tender their shares in support of the merger. The transaction is slated for ...